Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
565-04-012 ISMRM Abstract

A Multimodal MRI Radiomics-Clinical Nomogram for Predicting IVGC Response in Graves’ Ophthalmopathy: A Multicenter Study

Primary: Analysis Methods - Multi-Modal Learning with LLMs/VLMs
Secondary: Analysis Methods - Radiomics
565-04-012 · Neuroradiomics · Wednesday, 13 May, 2:35 PM–3:30 PM · Digital Posters Row F
Keywords: Radiomics Graves ophthalmopathy Intravenous sedation Nomogram
Accepted
Yanhu Zhou 1,2, Jing Zhang1, Kuanyu Che2, fei jia1, Xuelian Zhao1, Xiaojin Ma1
1The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China
2Department of Imaging, The First People's Hospital of Lanzhou City, LANZHOU, China
Presenting Author: Yanhu Zhou

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology.
2. Carballo MCS, de Sá BPC, Rocha DRTW, Arbex AK. Pathophysiology of Graves’ Ophthalmopathy: A Literature Review. Open Journal of Endocrine and Metabolic Diseases [Internet]. 2017 Jan;7(1):77–87. http://dx.doi.org/10.4236/ojemd.2017.71008 [doi]
3. Hou TY, Wu SB, Kau HC, Tsai CC. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves’ Ophthalmopathy. Biomedicines [Internet]. 2021 Dec;9(12):1871. Available from: http://dx.doi.org/10.3390/biomedicines9121871 [doi]
4. Chen J, Xu N, Sun H, Chen G. Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves’ Ophthalmopathy: A Meta-Analysis. Journal of Ophthalmology [Internet]. 2021 July;2021:1–8. Available from: http://dx.doi.org/10.1155/2021/9799274 [doi]
5. Mourits MPh, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clinical Endocrinology [Internet]. 1997 July;47(1):9–14. Available from: http://dx.doi.org/10.1046/j.1365-2265.1997.2331047.x [doi]
6. Alves Junior JM, Bernardo W, Villagelin D. Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis. J Clin Endocrinol Metab. 2024 Oct 15;109(11):2997–3009.
7. Nurannisa IA, Mulyani NS. Diagnosis dan Tatalaksana Terkini Oftalmopati Graves : Sebuah Tinjauan Pustaka. Syntax Literate ; Jurnal Ilmiah Indonesia [Internet]. 2025 Feb;10(2):1238–47. http://dx.doi.org/10.36418/syntax-literate.v10i2.56851 [doi]
8. Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel Approaches to the Management of Graves` Ophthalmopathy. HORMONES [Internet]. 2002 Apr;1(2):76–90. http://dx.doi.org/10.14310/horm.2002.1155 [doi]
9. Wiersinga WM. Evidence-based treatment of Graves ophthalmopathy. Nature Reviews Endocrinology [Internet]. 2009 Dec;5(12):653–4. http://dx.doi.org/10.1038/nrendo.2009.222 [doi]
10. Li X, Li S, Fan W, Rokohl AC, Ju S, Ju X, et al. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. International Ophthalmology [Internet]. 2022 Oct;43(4):1437–49. http://dx.doi.org/10.1007/s10792-022-02537-6 [doi]
11. Moon JH, Shin K, Lee GM, Park J, Lee MJ, Choung H, et al. Machine learning-assisted system using digital facial images to predict the clinical activity score in thyroid-associated orbitopathy. Scientific Reports [Internet]. 2022 Dec;12(1). http://dx.doi.org/10.1038/s41598-022-25887-8 [doi]
12. Hu H, Chen L, Zhang JL, Chen W, Chen HH, Liu H, et al. T2 -Weighted MR Imaging-Derived Radiomics for Pretreatment Determination of Therapeutic Response to Glucocorticoid in Patients With Thyroid-Associated Ophthalmopathy: Comparison With Semiquantitative Evaluation. J Magn Reson Imaging. 2022 Sept;56(3):862–72.
13. Yu D, Chen X, Lan L, Wang Y, Yu S, Mao B. Diagnostic Accuracy of MRI-Based Dixon and T2 Localization Techniques for Imaging Severity and Progression in Thyroid-Associated Ocular Diseases. Iranian Journal of Radiology [Internet]. 2025 Jan;22(1). http://dx.doi.org/10.5812/iranjradiol-151046 [doi]
14. Park J, Kim J, Ryu D, Choi H young. Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost. Front Endocrinol (Lausanne) [Internet]. 2023 Jan 31 [cited 2025 Apr 28];14:1079628. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928572/

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/565-04-012